Drug intelligence / Profile preview

Zenocort

Development stage: Unknown
Lead developer: Atro Pharma
Modality: Small Molecules
Administration: Oral

Overview

Zenocort is an oral corticosteroid tablet developed and marketed by Atro Pharma. It is a small molecule therapeutic that functions as an agonist of the glucocorticoid receptor, mediating potent anti-inflammatory and immunosuppressive effects. The medication is indicated for the management of various inflammatory conditions and autoimmune disorders. Zenocort is part of Atro Pharma's portfolio of formulated generic products and is designed to provide effective therapeutic benefits with a focus on minimizing the side effects typically associated with traditional corticosteroid therapy. It has received regulatory approval and is currently available in tablet form for oral administration.

Brand names: Zenocort
Other names: Zenocort Tablet

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on Zenocort.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zenocort.

Explore the full profile